Swiss vaccine candidates enter clinical trial phase
Research cooperation of a NRP 78 research team with the biotech company RocketVax AG to prepare clinical trials on two vaccine candidates.
Researchers from Bern, Geneva, Berlin and Riems (Germany) are developing two vaccine candidates against SARS-CoV-2. Thanks to a just-signed collaboration agreement with the Basel-based biotech company RocketVax AG, they can now be prepped for phase I of the clinical trials required for regulatory approval.
